… Activation of NLRP3 inflammasome is associated with disease severity in COVID-19
patients [40]. In addition, the presence of fatal NLRP3 inflammasome aggregates of COVID-19-…

… inflammasome activation evidenced by caspase-1/ASC-speck formation in severe COVID-19 …
In addition, we found that NLRP3 inflammasome-derived IL-1β secretion by SARS-CoV-2-…

… NLRP3 inflammasome mediated release of interleukin-1β (IL-1β) has been implicated in
various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea …

… affected by COVID-19 patients… inflammasome activation in patients with COVID-19. Melatonin
supplement (9 mg daily, orally) was provided for the patients hospitalized with a COVID-19 …

… microglial NLRP3 inflammasome activation… COVID-19 pre-clinical model, we established
the presence of virus in the brain together with microglial activation and NLRP3 inflammasome …

… and activity of the NLRP3 inflammasome complex and the … the coronavirus in the lung of
deceased persons with COVID-19. … COVID-19 and 5 corpses with the cause of death of COVID-…

… This suggests that inhibition of NLRP3 alone may have limited usefulness in COVID-19
sepsis, … NLRP3 inflammasome activation in pulmonary tissue of COVID-19 patients. (A and B) …

… Severe coronavirus disease 2019 (COVID-19) is characterized by … NLRP3 activation in
COVID-19 and clinical trials currently underway to target NLRP3 to treat severe COVID-19…

… NLRP3 inflammasome and cytokine storm are associated with the pathogenesis of COVID-19
… therapeutic potential to attenuate the inflammasome-induced acute respiratory distress …

… of inflammasome assembly in post-mortem COVID-19 lungs, we asked whether and how
metformin inhibits inflammasome … We show that metformin inhibited NLRP3 inflammasome …